2 Dividend Stocks Worth Doubling Down on Right Now
Not all dividend stocks were created equally. Some reduce or completely suspend payments when they encounter head winds. Others have much stronger businesses and continue to increase their dividends even if they face obstacles. Those looking for income want to stay away from the previous one and invest in the latter. It is a defective way to determine which one to look at the registry records.
Of course, the past does not guarantee anything, but companies with history to raise their dividends often have what needs to continue on this path. Consider the two dividend stocks with flawless identity information in that department and worth investing today: Medtronik(NYSE: MDT) And Johnson & Johnson(Nyse: jnj).
Image Source: Getty Images.
Medtronic, a leader Medical Device CompanyIt may face head winds due to the effect of tariffs on the financial consequences. However, the stock performed well this year. The latest financial results came before the analyst estimates, and the company even increased the guidance of earnings for the 2026 financial year that began on April 26th.
Although Medtronic has faced some problems in recent years, the health giant has taken steps to correct the situation. One of the focuses is to increase profitability. Medtronic has previously investigated to return some parts. Eventually, he settled for diabetes, consumer -oriented work and a business that produces margins lower than the rest of his operations. The initiative should help the company to increase the sub -line slightly.
Meanwhile, the job of Medtronic continues to be strong. The company is one of the largest medical device manufacturers covering more than one therapeutic field of operations. It constantly develops new products and markets, which results in consistent income and earnings.
An important approval that he must earn soon is the Hugo system, the Robotic Surgery (RAS) device; Considering this, it should have a significant impact on its financial consequences. There is an important white area in surgical robots. In addition, since most product sales depend on the procedure volume, the higher demand for medical procedures should be a strong tail wind for the company.
Medtronic has increased its dividends for 48 years, which is a line that points to a company that can eliminate any storm. 3.1% forward -looking yield of the stock, S&P 500Average 1.3%. This is the best dividend that stock investors can double today.
Johnson & Johnson also faces problems, including the general competition for the tariff and the general competition for immunology medical steel. Nevertheless, the drug giant performs well. The second quarter results were stronger and also increased its guidance for the 2025 fiscal year.
The pharmaceutical segment of J & J has been well diversified with its products of immunology, oncology, neuroscience, infectious diseases and more. Thanks to strong research and development (R) expenditures and important experience in this field, the company launches new products that help reduce the losses of those who fall from patent protection. The same thing has been done in recent years, so despite Stelara’s latest difficulties, the upper line continues to move in the right direction. This is a great sign for investors.
Johnson & Johnson’s medical device segment also contributes to its diversity. The company wants to sink its toes into the RAS market with the Ottava system, which is still undergoing clinical research in the USA.
It is true that J & J has faced legal and regulatory difficulties, including recent cases and price negotiations. Although these are worth watching, it is important to remember that Johnson & Johnson is the dividend king with a 62 dividend increase in a row. The company has gone through a lot of time, including the establishment of Medicare and Medicaid, which completely transform the US health sector.
Johnson & Johnson has survived and developed in the long run despite similar challenges in the past, and the company remains more than to fulfill its financial obligations. Therefore, it has a higher credit rating than the US government. Despite the latest winds, Johnson & Johnson continues to be the best revenue stock worth investing in the long run.
Imagine this before buying stock at Medtronic:
. Motley Fool Stock Advisor Analyst team determined what they believed Top 10 stocks Investors’ purchasing now… And Medtronic was not one of them. 10 shares that make the cut can produce monster returns in the coming years.
When think Netflix It made this list on December 17, 2004 … If you invested $ 1,000 during our advice, You have $ 649,657!* Or when Nvidia It made this list on April 15, 2005 … If you invested $ 1,000 during our advice, You would have $ 1,090,993!*
Now worth drawing attention Stock consultant Total average return 1,057A performance that breaks the market compared to 185% for -S & P 500. Don’t miss the last 10 lists, it can be used when you join Stock consultant.
Prosper Junior Bakiny Johnson & Johnson has positions. Motley Fool proposes Johnson & Johnson and Medtronic and proposes the following options: long January 2026 Medtronic and a short January 2026 call to $ 75 call Medtronic. Motley Fool’s Explanation policy.
